Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Table 1 Patient characteristics at baseline (ITT population)

Baseline characteristic	Natalizumab-treated patients (N = 222)
Age, years
Mean (SD)	34.0 (8.97)
Median (min, max)	32 (18, 64)
Female, n (%)	161 (72.5)
Time from MS symptom onset, mean (SD), years	3.0 (2.59)
Time from diagnosis of MS, mean (SD), years	1.6 (0.77)
Prior DMT treatments, n (%)	111 (50.0)
Number of relapses in the past 12 months, mean (SD)	1.4 (1.15)
EDSS score
Mean (SD)	2.0 (1.13)
Median (min, max)	2.0 (0.0, 6.5)
T1 lesion volume, median (min, max), mL	0.6 (0, 23.8)^a
T2 lesion volume, median (min, max), mL	3.9 (0, 61.6)^a
Gd + lesions, mean (SD)	2.5 (7.52)^a
Patients with no Gd + lesions, n (%)	114 (57.9)^a
SDMT score, mean (SD)	52.1 (14.02)^b
MSIS-29 score, mean (SD)
Physical	42.2 (19.05)^c
Psychological	21.9 (9.29)^c
Quality of life	64.2 (27.07)^c

DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, Gd + gadolinium-enhancing, ITT intent to treat, MS multiple sclerosis, SD standard deviation, SDMT Symbol Digit Modalities Test
^an = 197
^bn = 221
^cn = 217

ISSN: 1471-2377